1. Home
  2. IMCR vs NEOG Comparison

IMCR vs NEOG Comparison

Compare IMCR & NEOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$28.59

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Neogen Corporation

NEOG

Neogen Corporation

HOLD

Current Price

$8.68

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMCR
NEOG
Founded
2008
1981
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2016
1995

Fundamental Metrics

Financial Performance
Metric
IMCR
NEOG
Price
$28.59
$8.68
Analyst Decision
Buy
Buy
Analyst Count
10
4
Target Price
$66.33
$10.67
AVG Volume (30 Days)
369.3K
2.1M
Earning Date
05-07-2026
04-09-2026
Dividend Yield
N/A
N/A
EPS Growth
30.39
N/A
EPS
0.25
0.02
Revenue
$249,428,000.00
$894,661,000.00
Revenue This Year
$14.57
N/A
Revenue Next Year
$8.21
N/A
P/E Ratio
$118.60
$452.25
Revenue Growth
43.05
N/A
52 Week Low
$27.47
$4.53
52 Week High
$40.71
$11.43

Technical Indicators

Market Signals
Indicator
IMCR
NEOG
Relative Strength Index (RSI) 43.41 39.48
Support Level $28.90 $8.24
Resistance Level $34.35 $10.12
Average True Range (ATR) 1.31 0.36
MACD 0.11 -0.05
Stochastic Oscillator 35.41 7.26

Price Performance

Historical Comparison
IMCR
NEOG

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About NEOG Neogen Corporation

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.

Share on Social Networks: